Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study

Abstract

Background:

Leptomeningeal enhancement (LME) has been described as a biomarker of meningeal inflammation in multiple sclerosis (MS).

Objective:

The aim of this study was to (1) assess if LME is predictive of disability worsening in progressive MS (pMS) patients and (2) investigate the pathological substrates of LME in an independent post-mortem MS series.

Methods:

In total, 115 pMS patients were imaged yearly with 1.5T MRI, using post-contrast CUBE 3D FLAIR for LME detection. Endpoint: to identify the baseline variables predictive of confirmed disability worsening (CDW) at 24 months follow-up. Post-mortem, inflammation, and structural changes of the leptomeninges were assessed in 12 MS/8 control brains.

Results:

LME (27% of patients at baseline) was associated with higher EDSS and lower brain volume (nBV). LME was unchanged in most patients over follow-up. LME at baseline MRI was independently associated with higher risk of 24 months CDW (HR 3.05, 95% CI 1.36–6.84, p = 0.007) in a Cox regression, including age, nBV, T2 lesion volume, high-efficacy treatments, and MRI disease activity. Post-mortem, focal structural changes (fibrosis) of the leptomeninges were observed in MS, usually associated with inflammation (Kendall’s Tau 0.315, p < 0.0001).

Conclusions:

LME is frequently detected in pMS patients using 1.5T MRI and is independently predictive of disability progression. LME could result from both focal leptomeningeal post-inflammatory fibrosis and inflammation.

Keywords

Progressive multiple sclerosis disability leptomeningeal enhancement meningeal inflammation meningeal fibrosis brain volume

Get full access to this article

View all access options for this article.

References

Eisele

Griebe

Szabo

, et al. Investigation of leptomeningeal enhancement in MS: A postcontrast FLAIR MRI study. Neurology 2015; 84(8): 770–775.

Absinta

Vuolo

Rao

, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015; 85(1): 18–28.

Absinta

Cortese

ICM

Vuolo

, et al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology 2017; 88(15): 1439–1444.

Harrison

Wang

Fiol

, et al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. J Neuroimaging 2017; 27(5): 461–468.

Zivadinov

Ramasamy

Vaneckova

, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler 2017; 23(10): 1336–1345.

Makshakov

Magonov

Totolyan

, et al. Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis. Neurol Res Int 2017; 2017: 8652463.

Zurawski

Lassmann

Bakshi

. Use of magnetic resonance imaging to visualize leptomeningeal inflammation in patients with multiple sclerosis: A review. JAMA Neurol 2017; 74(1): 100.

Jonas

Izbudak

Frazier

, et al. Longitudinal persistence of meningeal enhancement on postcontrast 7T 3D-FLAIR MRI in multiple sclerosis. AJNR Am J Neuroradiol 2018; 39(10): 1799–1805.

Zivadinov

Ramasamy

Hagemeier

, et al. Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol 2018; 39(4): 642–647.

10.

Bergsland

Ramasamy

Tavazzi

, et al. Leptomeningeal contrast enhancement is related to focal cortical thinning in relapsing-remitting multiple sclerosis: A cross-sectional MRI study. AJNR Am J Neuroradiol 2019; 40(4): 620–625.

11.

Filippi

Brück

Chard

, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2019; 18(2): 198–210.

12.

Zivadinov

Bergsland

Carl

, et al. Effect of teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: A retrospective, observational, case-control pilot study. J Clin Med 2019; 8(3): 344.

13.

Zurawski

Tauhid

Chu

, et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler 2020; 26(2): 177–187.

14.

Hildesheim

Ramasamy

Bergsland

, et al. Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Mult Scler Relat Disord 2020; 47: 102653.

15.

Ighani

Jonas

Izbudak

, et al. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Mult Scler 2020; 26(2): 165–176.

16.

Titelbaum

Engisch

Schwartz

, et al. Leptomeningeal enhancement on 3D-FLAIR MRI in multiple sclerosis: Systematic observations in clinical practice. J Neuroimaging 2020; 30(6): 917–929.

17.

Okar

Reich

. Routine gadolinium use for MRI follow—up of multiple sclerosis: Point—The role of leptomeningeal enhancement. Am J Roentgenol 2022; 219: 24–25.

18.

Ineichen

Tsagkas

Absinta

, et al. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis. Neuroimage Clin 2022; 33: 102939.

19.

Zivadinov

Jakimovski

Ramanathan

, et al. Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study. Mult Scler Relat Disord 2022; 67: 104094.

20.

Christoph

Franca

Helly Noemi

, et al. Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients. Mult Scler 2023; 29: 63–73.

21.

Guseo

Jellinger

. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975; 211(1): 51–60.

22.

Serafini

Rosicarelli

Magliozzi

, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14(2): 164–174.

23.

Howell

Reeves

Nicholas

, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134(Pt. 9): 2755–2771.

24.

Pol

Schweser

Bertolino

, et al. Characterization of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Exp Neurol 2019; 314: 82–90.

25.

Bhargava

Kim

Reyes

, et al. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain 2021; 144(5): 1396–1408.

26.

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162–173.

27.

Kappos

Bar-Or

Cree

BAC

, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263–1273. Erratum in: Lancet. 2018; 392(10160): 2170.

28.

Smith

Jenkinson

Woolrich

, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23(Suppl. 1): S208–S219.

29.

Nonaka

Akima

Nagayama

, et al. Microvasculature of the human cerebral meninges. Neuropathology 2003; 23(2): 129–135.

30.

Wattjes

Ciccarelli

Reich

, et al.; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021; 20(8): 653–670.

31.

Bhargava

Wicken

Smith

, et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Mult Scler Relat Disord 2019; 30: 136–140.

32.

Bonnan

Ferrari

Courtade

, et al. No early effect of intrathecal rituximab in progressive multiple sclerosis (EFFRITE Clinical Trial). Mult Scler Int 2021; 2021: 8813498.

33.

Peters

Pitcher

Sullivan

, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011; 35(6): 986–996.

34.

Pikor

Astarita

Summers-Deluca

, et al. Integration of Th17- and lymphotoxin-derived signals initiates meningeal-resident stromal cell remodeling to propagate neuroinflammation. Immunity 2015; 43(6): 1160–1173.

35.

Dorrier

Jones

Pintarić

, et al. Emerging roles for CNS fibroblasts in health, injury and disease. Nat Rev Neurosci 2022; 23(1): 23–34.

36.

Wattjes

Killestein

. Imaging of meningeal inflammation should become part of the routine MRI protocol—No. Mult Scler 2019; 25(3): 331–333.

37.

Suzuki

Ishii

Ottomo

, et al. Changes in the subarachnoid space after experimental subarachnoid haemorrhage in the dog: Scanning electron microscopic observation. Acta Neurochir (Wien) 1977; 39(1–2): 1–14.

38.

Rocca

Battaglini

Benedict

, et al. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology 2017; 88(4): 403–413.

39.

Sastre-Garriga

Pareto

Battaglini

, et al.; MAGNIMS study group. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 2020; 16(3): 171–182.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB

0.02 MB